benralizumab
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Eosinophilic Asthma
Conditions
Severe Eosinophilic Asthma
Trial Timeline
Dec 20, 2025 → Dec 31, 2028
NCT ID
NCT07214753About benralizumab
benralizumab is a pre-clinical stage product being developed by AstraZeneca for Severe Eosinophilic Asthma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07214753. Target conditions include Severe Eosinophilic Asthma.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444567 | Phase 3 | Recruiting |
| NCT07214753 | Pre-clinical | Recruiting |
| NCT06512883 | Phase 3 | Recruiting |
| NCT06465485 | Phase 3 | Active |
| NCT05273359 | Phase 2 | UNKNOWN |
| NCT05384938 | Approved | Completed |
| NCT05932849 | Pre-clinical | Completed |
| NCT04305405 | Phase 3 | Completed |
| NCT04102800 | Approved | Completed |
| NCT03928262 | Phase 1 | Completed |
| NCT03557307 | Phase 3 | Completed |
| NCT03327701 | Phase 3 | UNKNOWN |
| NCT03010436 | Phase 2 | UNKNOWN |
| NCT02918071 | Phase 3 | Completed |
| NCT02869438 | Phase 3 | Completed |
| NCT02821416 | Phase 3 | Completed |
| NCT02417961 | Phase 3 | Completed |
| NCT02130882 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Severe Eosinophilic Asthma